Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

Université de Montréal

$105,000.00

Unprecedented role for the novel lactate receptor GPR81 in protecting against age-related macular degeneration.

FY 2019-20

Summary
Complete or partial loss of vision is a heavy burden on the individual and society. In this regard, age-related macular degeneration (AMD) is the leading cause of vision loss in industrialized countries. This is in a big part because of our primitive understanding from the basic pathology of this disease. This retinal disease typically occurs among people with age of 50 and older and results in a blurred vision or no vision in the center of the visual field. To this day, available therapeutic interventions fail to completely treat this condition. Briefly, AMD is defined in two clinical forms, where one does not exclude the other, which are: "the dry form" and "the wet forms". Although each of these forms have their peculiarities, both ultimately converge toward the detachment of the retina. The choroid, a layer of tissue underlying the retina which supplies blood, is often affected in this disease. Inflammation (pain, heat, swelling, etc.) occurring between the retina and the choroid frequently causes irreversible damage. When the retina loses its oxygen supply, lactate, a molecule released when cells lack oxygen, is produced. To date, the properties of this metabolite have not been defined in terms of anti-inflammatory. However, a lactate-binding receptor, named GPR81, has recently been discovered and our results indicate it could reduce this inflammation and have roles in protecting the retina against this kind of condition. Thus, this research project will study the underlying mechanism of GPR81 in AMD pathogenesis and would explore possible therapeutic value of GPR81 for AMD.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
417062
Name
Prairie Élizabeth
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Unprecedented role for the novel lactate receptor GPR81 in protecting against age-related macular degeneration.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Amd; Angiogénèse; Choroïde; Chronis Hypoxia; Gpr81; Lactate; Neovascularization; Ophtalmologie; Oxidant Stress; Vision
Abstract
Complete or partial loss of vision is a heavy burden on the individual and society. In this regard, age-related macular degeneration (AMD) is the leading cause of vision loss in industrialized countries. This is in a big part because of our primitive understanding from the basic pathology of this disease. This retinal disease typically occurs among people with age of 50 and older and results in a blurred vision or no vision in the center of the visual field. To this day, available therapeutic interventions fail to completely treat this condition. Briefly, AMD is defined in two clinical forms, where one does not exclude the other, which are: "the dry form" and "the wet forms". Although each of these forms have their peculiarities, both ultimately converge toward the detachment of the retina. The choroid, a layer of tissue underlying the retina which supplies blood, is often affected in this disease. Inflammation (pain, heat, swelling, etc.) occurring between the retina and the choroid frequently causes irreversible damage. When the retina loses its oxygen supply, lactate, a molecule released when cells lack oxygen, is produced. To date, the properties of this metabolite have not been defined in terms of anti-inflammatory. However, a lactate-binding receptor, named GPR81, has recently been discovered and our results indicate it could reduce this inflammation and have roles in protecting the retina against this kind of condition. Thus, this research project will study the underlying mechanism of GPR81 in AMD pathogenesis and would explore possible therapeutic value of GPR81 for AMD.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Prairie, Élizabeth
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Université de Montréal - $105,000 Grant (2019-20) | Canada Spends